Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis, PeptiDream Conclude License Deal for Drug Discovery Platform Technology
April 6, 2015
- Eisai, Niigata Univ. Finds Correlation of Cognitive Function with Plasma Desmosterol Levels in Alzheimer’s Disease Patients
April 6, 2015
- Astellas Signs Option Deal with US Cancer Center for Monoclonal Antibody Drug for Acute Myeloid Leukemia
April 6, 2015
- Kaken Licenses Topical Hyperhidrosis Treatment from US Biotech
April 3, 2015
- Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
- Mochida Unveils New 3-Year Biz Targets, Price Revisions, Generic Penetration Weigh
April 2, 2015
- Kenichi Fujita Becomes President of Taisho Toyama
April 2, 2015
- Eli Lilly to Solely Distribute Cymbalta; Shionogi to Enhance Detailing Activities
April 2, 2015
- MTPC Licenses VMAT2 Inhibitor from Neurocrine Biosciences
April 2, 2015
- Takeda Transfers Mizusawa Shares to Osaka Gas Chemicals for 4.3 Billion Yen
April 2, 2015
- SGLT-2 Inhibitors Represent Only 0.6% of Diabetes Prescriptions at DPC Hospitals: Survey
April 1, 2015
- Lupin Group’s Kyowa Sees Japan-India Collaboration as Key to Survival: Pres.
April 1, 2015
- Takecab Ranks 1st for Second Month in a Row: Anterio February Ranking
April 1, 2015
- Ajinomoto, Kissei Tie Up to Develop, Market Ulcerative Colitis Treatments
April 1, 2015
- Denka Seiken Develops Prototype of Rapid Diagnostic Agent for Ebola Virus
April 1, 2015
- Fujifilm to Buy US iPS Cell Manufacturer Cellular Dynamics
March 31, 2015
- Eisai’s Lenvima Gains Positive Opinion from CHMP
March 31, 2015
- Taisho Partners with Teijin to Comarket Patch Formulation Containing S-Flurbiprofen
March 31, 2015
- Hisamitsu to Rejuvenate Management with Nakatomi Junior as President
March 30, 2015
- Ichiro Otsuka Becomes Chairman of Otsuka Holdings
March 30, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…